Enjoy complimentary customisation on priority with our Enterprise License!
The anti-obesity drugs market size is forecast to increase by USD 13.69 billion at a CAGR of 12.5% between 2022 and 2027. The market's trajectory is influenced by several pivotal factors. Firstly, the growing obese population serves as a significant driver, creating a heightened demand for solutions to address weight management and related health issues. However, the use of bariatric surgery remains limited, primarily reserved for cases of morbid obesity due to stringent criteria and associated risks. Additionally, the market is constrained by a limited number of approved drugs, posing challenges for pharmaceutical companies seeking to develop effective treatments for obesity and its complications. These factors collectively shape the landscape of the market, highlighting the need for innovative approaches and interventions to meet the evolving needs of individuals grappling with weight-related health concerns.
To learn more about this report, Download Market Research Report Sample PDF
The market report extensively covers market segmentation by type (class III anti-obesity drugs, class II anti-obesity drugs, and class I anti-obesity drugs), drug class (peripherally acting drugs and centrally acting drugs), and geography (North America, Europe, Asia, and Rest of World (ROW)).
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Key offering - The SCOHIA PHARMA Inc. company offers IMCIVREE treatment which is designed to cure obesity disease as its key offering under the anti-obesity drug segment. Under this segment, the company is involved in offering the specialization in bio venture with great expertise in the field of lifestyle-related diseases such as cardiovascular, metabolic, and renal diseases.
Key Offering -The Alvogen company offers different types of pharmaceutical products including developing, manufacturing, and selling generic, brand, over-the-counter (OTC), and biosimilar products.It also offers Qsymia medicine as a prescription which is designed for the treatment of disease.
The report also includes detailed analyses of the competitive landscape of the market and information about 15 market companies, including:
The market witnesses a surge in demand driven by the escalating prevalence of overweight globally. With lifestyle-related illnesses on the rise, the market benefits from a robust pipeline for novel treatments targeting appetite, metabolism, and fat absorption. However, challenges persist, including the complexity of energy imbalance and chronic diseases like diabetes and arthritis. Lifestyle factors such as stress, smoking, and drinking exacerbate the global endemic of obesity, underscoring the urgent need for effective anti-obesity medications to combat this growing health crisis. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The use of bariatric surgery limited for morbid obesity is driving the market growth. Morbid obesity is on the rise in the US and may shorten life expectancy. Combinations of diet therapies, exercise, and pharmacotherapy are widely used to treat it, but significant weight loss is often limited and temporary. It is a chronic condition affecting breathing, physical activity, and sleep, and can lead to serious health issues like type 2 diabetes, high blood pressure, back pain, etc. Bariatric surgery offers a cost-effective and successful solution to these problems and includes techniques such as laparoscopic sleeve gastrectomy, laparoscopic Roux-en-Y gastric bypass, and laparoscopic adjustable gastric banding. It is considered safe and effective, even in patients with multiple sclerosis, and is widely accepted as the most effective treatment for those with extreme obesity. The use of bariatric surgery is therefore increasing.
An increase in childhood obesity and morbid obesity incidence is the key trend in the market. The prevalence of clinically severe obesity is increasing in the US, although at a slower pace than prior to 2005. Severe and morbid obesity have more serious health consequences than moderate obesity. The prevalence of morbid obesity has been increasing globally in the last 20 years. In the UK, owing to the increased consumption of foods high in fat, salt, or sugar.
The increase in morbid obesity could be linked to increased utilization of healthcare resources in terms of difficulty to transport, transfer, and examine. Routine tasks, including drawing blood, getting X-rays, computed tomography (CT) scans, and emergency department bedside ultrasound, could be more time-consuming in patients with morbid obesity. Other challenges in this patient segment include cardiovascular dysfunction, hypertension, and pulmonary disorders such as respiratory failure and hypoventilation. Thus, increasing incidences of childhood and morbid obesity will increase the demand, which in turn will propel the growth of the market during the forecast period.
Limited reimbursement for anti-obesity drugs is the major challenge impeding the market growth. Obesity is the most prevalent chronic disease worldwide. Although the US is the major market, the challenges associated with the reimbursement for anti-obesity drugs are more in the US. Bariatric surgery can recover weight-related comorbid diseases and is lifesaving, but the concern about the financial burden remains.
The patient's access to obesity medication through health insurance plan coverage has a barrier to the adoption of medications. In the US payer atmosphere that includes private, government, and employer-based reimbursement schemes and patient movement between these schemes, there is an unwillingness to pay for bariatric surgery and obesity pharmacotherapy due to the perception that obesity is a cosmetic or lifestyle issue, which led payers to limit coverage. Thus, such factors might hamper the growth of the market during the forecast period.
The market research report includes the adoption lifecycle of the market research and growth, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth and forecasting strategies.
Customer Landscape
In the market, a multitude of factors shape the landscape, with the prevalence of obesity serving as a significant driver for demand. Pharmaceutical companies are driven by a robust pipeline for novel treatments targeting various aspects of obesity, including appetite, metabolism, and fat absorption. Chronic diseases such as diabetes mellitus and arthritis underscore the urgent need for effective interventions to combat obesity-related complications like insulin resistance and glucose intolerance. The market addresses diverse demographics, including children and adolescents, who are increasingly affected by lifestyle-related illnesses due to factors like energy imbalance and caloric intake. Amid a global endemic of obesity, the market focuses on developing medications that tackle obesity holistically, aiming to curb the rising tide of overweight and obesity worldwide.
The market share growth by the class III anti-obesity segment will be significant during the forecast period. Class III anti-obesity drugs is the largest segment of the market and will continue to remain the largest segment during the forecast period. The majority of the drugs offered in the market are targeted at patients categorized under class III obesity. Also, the increase in R and D by manufacturers for new anti-obesity drugs may boost the growth of the global class III market during the forecast period.
Get a glance at the market contribution of various segments Request Market Research Report Sample PDF
The class III anti-obesity drug segment was valued at USD 5.76 billion in 2017 and continued to grow until 2021. However, its growth momentum is expected to slow down during the forecast period. The main reason for this decline could be the rise in morbid obesity cases. As pharmacotherapy is limited in its ability to decrease BMI and only bariatric surgery can effectively treat morbid obesity with low complications and death rates, the class III anti-obesity drug segment of the market is expected to decrease during the forecast period.
For more insights on the market share of various regions Request Market Research Report Sample now!
North America is estimated to contribute 68% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. North America is the largest geographical segment of the market and will continue to remain the largest segment during the forecast period. The market is anticipated to grow at moderate growth owing to the rising obese population in North America. Approved drugs such as Qsymia, Saxenda, and BELVIQ generated the highest revenues in North America. The US, Mexico and Canada are the major contributors to the growth of the regional market.
The US holds the largest market share in the market in North America in 2022. Due to the presence of the highest obese population, the US will continue to lead the global as well as the North American market. Also, due to the availability of FDA-approved drugs and the high prevalence and incidence of adult and childhood obesity, the US is expected to continue to dominate the market during the forecast period.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD Billion" for the period 2023 to 2027, as well as historical data from 2017 to 2021 for the following segments
The market addresses the urgent need to combat obesity, a condition linked to various chronic and debilitating problems including heart disease, cancer, and sleep apnea. Pharmaceutical companies focus on developing weight-loss medicines targeting pathways such as dopamine, norepinephrine, and serotonin activity with centrally acting and peripherally acting anti-obesity drugs. These medications are administered via oral or subcutaneous routes and are available as prescription or over the counter drugs through various channels including retail pharmacies, online pharmacies, and hospital pharmacy. The market faces challenges due to stringent drug approval policies and concerns regarding side effects like increased heart rate and constipation. The ideal anti-obesity medicine aims for sustained weight loss while minimizing adverse effects, addressing the critical need for effective obesity management solutions. In addition, pharmaceutical advancements in centrally acting anti-obesity drugs aim to target neural pathways involved in appetite regulation, administered through oral or subcutaneous routes.
Moreover, these drugs, including glucagon-like peptide-1 (GLP-1) receptor agonists and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, are in various stages of the pipeline phase. Alongside prescription medications, the availability of over-the-counter drugs provides options for consumers seeking weight management solutions. However, the market grapples with challenges such as the prevalence of unhealthy diets, which contribute to conditions like Gall bladder diseases and obesity-associated cancers highlighted by organizations like the Centers for Disease Control and Prevention (CDC) and the World Obesity Federation. As obesity continues to be a major risk factor for cardiovascular disease, cancers, and other severe illnesses, there is a pressing need for comprehensive approaches encompassing medication, lifestyle modifications, and public health interventions to address the global epidemic.
Market Scope |
|
Report Coverage |
Details |
Page number |
162 |
Base year |
2022 |
Historic period |
2017-2021 |
Forecast period |
2023-2027 |
Growth momentum & CAGR |
Accelerate at a CAGR of 12.5% |
Market growth 2023-2027 |
USD 13.69 billion |
Market structure |
Fragmented |
YoY growth 2022-2023(%) |
11.52 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 68% |
Key countries |
US, Canada, Germany, UK, and China |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
Alvogen Iceland ehf, Amgen Inc., AstraZeneca, Boehringer Ingelheim International GmbH, Cadila Healthcare Ltd., Eli Lilly and Co., Empros Pharma AB, ERX Pharmaceuticals Inc., Gelesis Inc., GlaxoSmithKline Plc, Innovent Biologics Ltd., Novo Nordisk AS, Rhythm Pharmaceuticals Inc., SCOHIA PHARMA Inc., VIVUS LLC, and LG Chem |
Market dynamics |
Parent market growth analysis, Market Forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the market forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Get access to Report Sample PDF !
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Type
7 Market Segmentation by Drug Class
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.